Clean Biologics offshoot Clean Cells has acquired Karyologic, a US-based specialised karyotyping service provider.
The company, based in Durham North Carolina, will expand Clean Cells' operational footprint and fuel the company's international growth.
Through the acquisition of Karyologic, Clean Cells will be able to offer its customers cytogenic testing services essential to developers of next-generation biologics and cell therapies.
By offering enhanced karyotype services to its clients throughout the US and North America, Clean Cells will be able to capitalise on this key market and offer more comprehensive services to the region.
The companies, following the successful closing of the acquisition on March 31, 2025, will immediately being the integration of operations.
"This acquisition marks an exciting new chapter for Clean Cells as we strengthen our operational footprint in the US. Our ambition is clear: to support our clients' innovation in biologics with exceptional service capabilities both in Europe and North America," said Joseph Jammal, CEO of Clean Cells.
"Joining Clean Cells allows us to combine our expertise in cytogenetic analysis with their broad biologics service portfolio," added CEO of Karyologic, Elizabeth Gonzalez.
"This union ensures we deliver even greater value and reliability to our clients as part of a globally recognised organisation."
Denis Ribon, Managing Partner at ARCHIMED, Clean Cells' majority investor, concluded: "This acquisition aligns perfectly with our commitment to growing Clean Cells' international presence and strengthening its position in the rapidly evolving biologics sector."